^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2020
    Title:

    Abstract 800: Exploiting the proteasome to overcome RAS and WT1 mutation mediated resistance to FLT-3 inhibition in acute myeloid leukemia

    Published date:
    06/23/2020
    Excerpt:
    Similar experiments were carried out on cell lines MV411 (Flt3ITD/MLL), THP-1 and OCI-AML3 (both NRAS)…We also observed sensitivity to Ixazomib in THP-1 and OCI-AML3, while MV4-11 was sensitive to TAK-659 but relatively resistant to Ixazomib alone.
    DOI:
    10.1158/1538-7445.AM2020-800